41 completed, 11 unknown, 10 recruiting, 8 terminated. 40 Phase 2, 19 Phase 1, 8 Not applicable, 5 Phase 3.
Follow Graft-Versus-Host Disease: new trials by email Literature Review of Graft-Versus-Host Disease trials Research Report on Graft-Versus-Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ruxolitinib in Patients With Graft-Versus Host Disease Graft-Versus-Host Disease | Recruiting | Novartis Pharmaceuticals | 395 | 2026-05-11 | 2026-06-08 | |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Moxibustion, Moxibustion Twice Daily Plus Best Available Treatment (BID Group), Best Available Treatment (BAT) - Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 42 | 2025-09-01 | 2026-05-07 |
| Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease HORIZONS Intervention, Minimally enhanced usual care - Bone Marrow Transplant Complications, Graft-versus-Host Disease | Not applicable | Recruiting | Massachusetts General Hospital | 350 | 2025-08-13 | 2026-09-24 |
| Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease Rovadicitinib, Imatinib, Methotrexate - Graft-versus-host Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 182 | 2024-11-20 | 2025-12-08 |
| Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT TCRαβ Depleted haploidentical HCT - Graft-Versus-Host Disease, Hematopoietic Stem Cell Transplantation | Not applicable | Recruiting | Sijia Gu | 110 | 2024-05-26 | 2024-05-29 |
| Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade Cyclophosphamid - Graft-versus-host Disease, Hematological Malignancies | Phase 2 | Unknown | Beijing 302 Hospital | 22 | 2024-02-28 | 2024-02-20 |
| De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil - Graft-versus-host Disease | Phase 2 | Active not recruiting | Medical College of Wisconsin | 56 | 2023-08-29 | 2026-03-12 |
| To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability SHR0302 - Graft-versus-host Disease | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 16 | 2023-05-29 | 2023-12-08 |
| A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea ruxolitinib - Graft-versus-Host Disease | Completed | Novartis Pharmaceuticals | 140 | 2023-04-07 | 2026-08-13 | |
| Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant Graft-versus-host Disease | Active not recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 88 | 2023-01-23 | 2026-01-16 | |
| A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant Photobiomodulation Therapy, Placebo sham device - Graft-Versus-Host Disease, GVHD | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 44 | 2022-12-22 | 2026-05-22 |
| Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Cyclophosphamide, Abatacept, Bortezomib - Graft-versus-host Disease | Phase 1 / Phase 2 | Recruiting | Northwell Health | 74 | 2022-03-13 | 2026-05-29 |
| Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) Neihulizumab, 3 mg/kg, Neihulizumab, 6 mg/kg, Neihulizumab, 9 mg/kg - Graft-versus-host Disease | Phase 1 | Completed | Sameem M. Abedin, MD | 12 | 2020-12-14 | 2024-10-01 |
| Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention - Graft-versus-host Disease | Phase 1 / Phase 2 | Completed | NYU Langone Health | 46 | 2020-09-16 | 2024-10-16 |
| Safety and Efficacy of Fecal Microbiota Transplantation Fecal Microbiota Transplantation - Crohn Disease, Ulcerative Colitis | Not applicable | Recruiting | Chinese University of Hong Kong | 450 | 2019-07-15 | 2024-08-22 |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies Prophylactic DLI - Donor Lymphocyte Infusion, Peripheral Blood Stem Cell Transplantation | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2019-01-01 | 2018-12-13 |
| An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) Defibrotide, Standard of Care - Graft-versus-host Disease, Acute-graft-versus-host Disease | Phase 2 | Completed | Jazz Pharmaceuticals | 152 | 2018-02-21 | 2021-08-18 |
| Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis Extracorporeal photophoresis (ECP) - Graft-Versus-Host Disease | Not applicable | Completed | Oslo University Hospital | 158 | 2017-06-21 | 2025-09-24 |
| Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant donor lymphocyte infusion - Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Unknown | Peking University People's Hospital | 40 | 2017-03-01 | 2020-03-10 |
Showing 20 of 75. Sign in to see all of them.
Graft vs Host Disease (75) · Hematologic Neoplasms (7) · Leukemia (5) · Lymphoma (4) · Recurrence (4) · Bronchiolitis Obliterans Syndrome (3) · Myelodysplastic Syndromes (3) · Neoplasms (2) · Alcoholism (1) · Alopecia (1) · Arthritis, Psoriatic (1) · Autistic Disorder (1) · Autoimmune Diseases (1) · Bronchiolitis Obliterans (1) · Carcinoma, Renal Cell (1)
Immune System Diseases (74) · Hemic and Lymphatic Diseases (13) · Hematologic Diseases (12) · Neoplasms (12) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (8) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Respiratory Tract Diseases (5) · Bronchial Diseases (4) · Bronchiolitis (4) · Bronchitis (4) · Disease Attributes (4) · Immunoproliferative Disorders (4) · Lung Diseases (4)
Tacrolimus (10) · Cyclophosphamide (7) · Mycophenolic Acid (7) · Photopheresis (5) · Cyclosporine (4) · Methotrexate (4) · Methoxsalen (3) · Sirolimus (3) · Abatacept (2) · Bortezomib (2) · Etanercept (2) · Maraviroc (2) · Pentostatin (2) · Surveys and Questionnaires (2) · Whole-Body Irradiation (2)
M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · National Heart, Lung, and Blood Institute (NHLBI) (4) · University of Michigan Rogel Cancer Center (3) · Astellas Pharma Inc (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Hadassah Medical Organization (2) · Karolinska Institutet (2) · Mallinckrodt (2) · MedImmune LLC (2) · Medical College of Wisconsin (2) · Memorial Sloan Kettering Cancer Center (2) · Mesoblast, Inc. (2) · Novartis Pharmaceuticals (2) · Ohio State University Comprehensive Cancer Center (2)
United States (43) · China (7) · Germany (6) · Belgium (3) · Israel (3) · Italy (3) · Japan (3) · Portugal (3) · Spain (3) · United Kingdom (3) · Australia (2) · Austria (2) · Canada (2) · France (2) · Russia (2)
Amin Alousi, MD (2) · Craig Hofmeister, MD (2) · J. Bruce McClain, M.D. (2) · Sameem Abedin, MD (2) · A. Samer Al-Homsi, MD, MBA (1) · Alina Markova, MD (1) · Andre Larochelle, M.D. (1) · Andromachi Scaradavou, MD (1) · Areej El-Jawahri MD (1) · Arnon Nagler, MD (1) · Attaphol Pawarode, M.D. (1) · Augustin Ferrant, MD, PhD (1) · Ayman Saad, MD (1)
PMID 18042798, PMID 18541197, PMID 18621929, PMID 22155140, PMID 22242033, PMID 22784116, PMID 23000649, PMID 23588536, PMID 25170121, PMID 25425214, PMID 26071480, PMID 27662016, PMID 30710687, PMID 31972009, PMID 32044400, PMID 32081787, PMID 32573983, PMID 32873915, PMID 36372356, PMID 36519326, PMID 37163349, PMID 40922037, PMID 42137823
R01HD074587 (1), U01HL069294 (1), U24CA076518 (1)